GEHC
GE HealthCare Technologies Inc.
GEHC's fundamentals are mixed: free cash flow grew 35%, but earnings per share fell 2.5%. At 17x earnings, it's trading in line with its usual 19x. Analysts expect earnings growth.
GEHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
GEHC's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
GEHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $71.95 | -12% |
| Forward | 15x | $81.84 | — |
| Current | 17x | $81.84 | — |
| Fair | 19x | $87.98 | +7.5% |
| Expensive | 24x | $111 | +36% |
Historical ranges are pointers, not guarantees.
GEHC's PE is in its fair range at 17x. If earnings grow as analysts expect, today's price would be 15x next year's earnings, in its cheap range.
GEHC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for GEHC, with profitability improving.
GEHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.35 | +13% |
| Q3 2026 | $4.73 | -2.5% |
| Q2 2026 | $4.35 | -11% |
| Q1 2026 | $4.17 | -12% |
| Q4 2025 | $4.55 | +4.8% |
| Q3 2025 | $4.85 | +33% |
| Q2 2025 | $4.89 | +42% |
| Q1 2025 | $4.76 | +39% |
| Q4 2024 | $4.34 | +43% |
GEHC earned $4.73 per share over the past year, down 2.5% from the year before.
GEHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.5B | +7.2% |
| Q2 2026 | $5.3B | +5.8% |
| Q1 2026 | $5.1B | +7.4% |
| Q4 2025 | $5.7B | +7.1% |
| Q3 2025 | $5.1B | +5.8% |
| Q2 2025 | $5B | +3.5% |
| Q1 2025 | $4.8B | +2.7% |
| Q4 2024 | $5.3B | +2.2% |
GEHC's revenue has grown year over year for 10 quarters in a row: $5.5B last quarter, up 7.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +1.9 points |
| Q2 2026 | 14% | +0.9 points |
| Q1 2026 | 10% | -3.1 points |
| Q4 2025 | 15% | -0.6 points |
| Q3 2025 | 13% | -1.2 points |
| Q2 2025 | 13% | +0.5 points |
| Q1 2025 | 13% | +1.6 points |
| Q4 2024 | 15% | +1.8 points |
GEHC's operating margin was 15% last quarter, up 1.9 points from the same quarter a year ago.
GEHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $793M | +64% |
| Q2 2026 | $68M | +750% |
| Q1 2026 | $112M | +14% |
| Q4 2025 | $916M | +13% |
| Q3 2025 | $483M | -26% |
| Q2 2025 | $8M | +$191M |
| Q1 2025 | $98M | -64% |
| Q4 2024 | $811M | -15% |
GEHC generated $1.9B in free cash flow over the past year, up 35% from the year before.
GEHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -1M shares |
| 1 year | -0.9% | -4M shares |
| 3 years | -1.1% | -5M shares |
| 5 years | -0.4% | -1.7M shares |
GEHC has 453M diluted shares, down 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $200M |
| Q1 2026 | $100M |
| Q4 2025 | — |
| Q3 2025 | $100M |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
GEHC spent $300M buying back its own shares over the past year.
GEHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.0x | Moderate |
| Q2 2026 | 2.4x | Moderate |
| Q1 2026 | 2.4x | Moderate |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 2.5x | Moderate |
| Q2 2025 | 2.6x | Moderate |
| Q1 2025 | 2.5x | Moderate |
| Q4 2024 | 2.4x | Moderate |
GEHC's net debt is about 2.0 years of its operating earnings (EBITDA), down from 2.5 years a year ago.
GEHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.0 | Neutral |
| Stochastic | 82.0 | Overbought |
GEHC's weekly RSI is 65 (neutral) and its Stochastic is 82 (overbought).
GEHC PE vs Healthcare Sector
| Metric | GEHC | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 33% below |
| PE % | 42 | 42 | Same percentile |
GEHC is trading at 17x earnings, a 33% discount to the Healthcare sector's median of 26x.
GEHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.3 | 13% above |
| 20 week MA | $69.5 | 18% above |
| 50 week MA | $72.1 | 13% above |
| 100 week MA | $74.2 | 10% above |
| 200 week MA | $76.6 | 6.9% above |
GEHC has climbed back above all five of its weekly moving averages, and it's now 6.9% above its 200-week average.
GEHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $58.4 | $77.3 | +32% |
| 2024 | $77.3 | $79.5 | +2.8% |
| 2025 | $79.5 | $83.6 | +5.2% |
| 2026 YTD | $83.6 | $81.8 | -2.1% |
GEHC has finished every year since 2023 higher, and it's down 2.1% so far in 2026.